This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 49/3/432    most recent 01.HYP.0000256956.61872.aav1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, T. J. Articles by Vasan, R. S. Search for Related Content PubMed PubMed Citation Articles by Wang, T. J. Articles by Vasan, R. S. Related Collections Clinical Studies Epidemiology

(Hypertension. 2007;49:432.)
© 2007 American Heart Association, Inc.

Original Articles

Multiple Biomarkers and the Risk of Incident Hypertension

Thomas J. Wang; Philimon Gona; Martin G. Larson; Daniel Levy; Emelia J. Benjamin; Geoffrey H. Tofler; Paul F. Jacques; James B. Meigs; Nader Rifai; Jacob Selhub; Sander J. Robins; Christopher Newton-Cheh; Ramachandran S. Vasan

From the Framingham Heart Study (T.J.W., P.G., M.G.L., D.L., E.J.B., S.J.R., C.N.-C., R.S.V.), Framingham, Mass; the Divisions of Cardiology (T.J.W., C.N.-C.) and General Medicine (J.B.M.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston; the Department of Mathematics and Statistics (P.G., M.G.L.), Boston University, Boston; the National Heart, Lung, and Blood Institute (D.L.), Bethesda, Md; Royal North Shore Hospital (G.H.T.), Sydney, Australia; Jean Mayer Department of Agriculture Human Nutrition Research Center on Aging (P.F.J., J.S.), Tufts University, Boston, Mass; the Department of Laboratory Medicine (N.R.), Children’s Hospital, Harvard Medical School, Boston, Mass; and the Preventive Medicine and Cardiology Sections (D.L., E.J.B., R.S.V.), Division of Endocrinology, Nutrition, and Diabetes (S.J.R.), Boston Medical Center, Boston University School of Medicine, Mass.

Correspondence to Thomas J. Wang, Cardiology Division, GRB-800, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114. E-mail tjwang{at}partners.org

An understanding of mechanisms underlying the development of essential hypertension is critical for designing prevention and treatment strategies. Selected biomarkers may be elevated before the onset of hypertension, but previous studies are limited by cross-sectional designs or a focus on single biomarkers. We prospectively studied 1456 nonhypertensive individuals who had baseline measurement of 9 biomarkers: C-reactive protein (inflammation); fibrinogen (inflammation and thrombosis); plasminogen activator inhibitor-1 (fibrinolytic potential); aldosterone, renin, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide (neurohormonal activity); homocysteine (renal function and oxidant stress); and urinary albumin/creatinine ratio (glomerular endothelial function). Incident hypertension, defined as blood pressure 140/90 mm Hg or antihypertensive therapy, developed in 232 participants over a mean follow-up of 3 years. After adjustment for clinical risk factors, the biomarker panel was significantly associated with incident hypertension (P=0.002). Three (of 9) biomarkers were significantly related to incident hypertension on backward elimination (multivariable-adjusted odds ratios, per SD increment in biomarker): C-reactive protein (1.26; 95% CI: 1.05 to 1.51), plasminogen activator inhibitor-1 (1.28; 95% CI: 1.05 to 1.57), and urinary albumin/creatinine ratio (1.21; 95% CI: 1.02 to 1.43). The incidence of hypertension was 4.5, 6.4, and 9.9 per 100 person years for participants with 0, 1, and 2 elevated biomarkers, respectively (elevation defined as 1 SD above the mean). The threshold of 2 elevated biomarkers for predicting hypertension was associated with high specificity (0.92) but low sensitivity (0.15). Biomarkers of inflammation, reduced fibrinolytic potential, and low-grade albuminuria are jointly associated with the incidence of hypertension. These data support the premise that abnormalities in multiple biological pathways antedate the onset of overt hypertension.

Key Words: epidemiology • hypertension • C-reactive protein • plasminogen activator inhibitor-1 • aldosterone • albuminuria

This article has been cited by other articles:

				E. Ingelsson, M. J. Pencina, G. H. Tofler, E. J. Benjamin, K. J. Lanier, P. F. Jacques, C. S. Fox, J. B. Meigs, D. Levy, M. G. Larson, et al. Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors: The Framingham Offspring Study Circulation, August 28, 2007; 116(9): 984 - 992. [Abstract] [Full Text] [PDF]

				X. Gao, L. Qi, N. Qiao, H. K. Choi, G. Curhan, K. L. Tucker, and A. Ascherio Intake of Added Sugar and Sugar-Sweetened Drink and Serum Uric Acid Concentration in US Men and Women Hypertension, August 1, 2007; 50(2): 306 - 312. [Abstract] [Full Text] [PDF]

				Are There Biomarkers That Portend Hypertension? Journal Watch Cardiology, March 6, 2007; 2007(306): 4 - 4. [Full Text]